Host responses to Mycobacterium infection in Zebrafish.

Information

  • Research Project
  • 9413295
  • ApplicationId
    9413295
  • Core Project Number
    R37AI054503
  • Full Project Number
    5R37AI054503-16
  • Serial Number
    054503
  • FOA Number
    PA-14-078
  • Sub Project Id
  • Project Start Date
    5/1/2017 - 7 years ago
  • Project End Date
    4/30/2022 - 2 years ago
  • Program Officer Name
    SINGLETON, KENTNER L
  • Budget Start Date
    5/1/2018 - 6 years ago
  • Budget End Date
    4/30/2019 - 5 years ago
  • Fiscal Year
    2018
  • Support Year
    16
  • Suffix
  • Award Notice Date
    4/19/2018 - 6 years ago
Organizations

Host responses to Mycobacterium infection in Zebrafish.

We have used the zebrafish model to detail the host-pathogen interface in tuberculosis, and our discoveries have led to a more nuanced understanding of the role of inflammation, macrophages and granulomas in infection. In so doing, we have also achieved a better understanding of fundamental host processes particularly those involving macrophages and inflammation. In this next phase of the grant, we will continue to characterize the role of newly-identified host factors that alter mycobacterial infection. Some of these were already identified but not fully characterized in the last funding period, and others will be identified in the zebrafish mutant screen that we are continuing now, using the comprehensive sequenced zebrafish mutant library that has been created by the Sanger Institute and made available to us. Comprehensive transcriptomics will also be carried out for us at the Sanger Institute with full bioinformatics support, leaving us to focus on the phenotypic characterization of the mutants with altered susceptibility. With advances in microscopic imaging capability that are continuously occurring in our laboratory, and the use of pharmacological approaches for additional pathway dissection and drug identification, we hope to have an accelerated pace of discovery during this next phase. RELEVANCE (See instnJctions): Tuberculosis is a leading cause of death worldwide and a growing global health concern. TB has been difficult to eradicate due to a combination of factors, including the development of antibiotic resistance. Our research proposes to identify strategies and molecules that can direct development of new classes of host-targeting drugs to treat TB.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R37
  • Administering IC
    AI
  • Application Type
    5
  • Direct Cost Amount
    250000
  • Indirect Cost Amount
    20000
  • Total Cost
    270000
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    855
  • Ed Inst. Type
  • Funding ICs
    NIAID:270000\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    NSS
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    UNIVERSITY OF CAMBRIDGE
  • Organization Department
  • Organization DUNS
    226552610
  • Organization City
    CAMBRIDGE
  • Organization State
  • Organization Country
    UNITED KINGDOM
  • Organization Zip Code
    CB2 1TN
  • Organization District
    UNITED KINGDOM